The episode opens with Manoush Zomorodi — NPR's TED Radio Hour host, two-time TED speaker, and guest curator for TED 2026 — framing a week-long series about living healthier in the high-tech era. She introduces Dr. Dhruv Khullar: practicing physician, Weill Cornell professor, and New Yorker writer known for his empathetic, measured take on hot-button medical topics. The preview teases the episode's core surprise: that GLP-1 drugs like Ozempic, already famous for treating diabetes and weight loss, are showing remarkable potential to quiet addictive cravings of all kinds. The hook is set before the talk even begins.

A pre-content sponsor block features three ads: Dell promotes the XPS laptop starting at $699 (student pricing from $599) via dell.com/deals; Walmart Business pitches its all-in-one business procurement platform at business.walmart.com; and Apple Card — issued by Goldman Sachs — promotes its unlimited daily cash back and titanium build, directing listeners to the Wallet app. These are standard paid integrations running ahead of the episode's TED Talk segment.

The centerpiece of the episode, Khullar's TED Talk opens with Mary — a patient who had failed rehab, AA, and Antabuse before enrolling in an Ozempic clinical trial and achieving sobriety ^{[1] — Dhruv Khullar "Mary had tried rehab, AA, and Antabuse — and failed every time. Then she enrolled in a clinical trial for Ozempic. Within weeks, the cravin…" 05:29 Play} . From there, Khullar unfolds the drug's origin story: discovered in the 1980s but unworkable until a Gila monster researcher found a peptide in lizard venom that lasted hours rather than minutes. That discovery unlocked a class of drugs now showing effects far beyond digestion — specifically in the brain's mesolimbic reward pathway. GLP-1s appear to blunt dopamine spikes across every major addiction: alcohol, cocaine, nicotine, gambling, even social media. One neuroscientist told Khullar this suggests addiction may have a single universal pathology. But Khullar urges caution: these 'moderation molecules' can become desire dampeners, and anhedonia is a real risk. He closes by invoking Aristotle — and then dismantling him: Aristotle never faced Doritos, TikTok, or fentanyl. Moderation today isn't just a virtue; it is, the science suggests, a physiological state ^{[2] — Dhruv Khullar "GLP-1s suggest that Aristotle's moderation, it's not just a virtue, it is a physiological state. It isn't just about character, it is about…" 14:44 Play} .

A mid-episode sponsor break features LinkedIn's HiringPro — which claims users are 24% less likely to need to reopen a role within 12 months — directing listeners to LinkedIn.com/TedTalk, followed by Gusto's payroll and benefits software offering 3 months free at gusto.com/tedtalks. Both ads target small business owners dealing with hiring and operations complexity.

Manoush Zomorodi opens the post-talk conversation by asking whether Mary was a patient or a journalistic contact. Khullar explains she was introduced through a clinical trial researcher. Mary's case was extreme: eating only 300–500 calories a day, she lost 55 pounds in five months and had to be taken off the drug due to excessive weight loss ^{[1] — Dhruv Khullar "Mary lost 55 lbs in 5 months: Trial participant Mary lost 55 pounds in just 5 months on Ozempic, ultimately having to stop due to excessive…" 19:25 Play} . But crucially, she maintained her sobriety after stopping. It's a nuanced data point: the drug worked dramatically, produced side effects serious enough to force discontinuation, and yet the behavioral change outlasted the medication. Manoush reflects on how this sounds miraculous to a general audience — and asks what, as a physician, made Khullar treat these stories as more than anecdote.

Manoush presses on the dopamine mechanism, and Khullar unpacks both what's known and what's still genuinely mysterious. Dopamine, he explains, isn't just about addiction — it governs motor function (disrupted in Parkinson's) and motivation broadly. The reductive 'just blunt dopamine spikes' narrative misses complexity. What makes GLP-1s surprising is that their effects seem to span alcohol, nicotine, cocaine, and social media — all different substances converging on the same pathway. Critically, it's not even fully clear whether or how GLP-1 molecules physically cross into the brain, meaning the mechanism may involve both direct brain action and gut-brain signaling. Khullar notes the gut-brain crosstalk — GLP-1 receptors in the pancreas, GI tract, and brain all play a role, and some addiction-relevant effects may come from signaling between the intestines and brain, not just the brain itself.

Manoush presses on the dopamine mechanism, and Khullar unpacks both what's known and what's still genuinely mysterious. Dopamine, he explains, isn't just about addiction — it governs motor function (disrupted in Parkinson's) and motivation broadly. The reductive 'just blunt dopamine spikes' narrative misses complexity. What makes GLP-1s surprising is that their effects seem to span alcohol, nicotine, cocaine, and social media — all different substances converging on the same pathway. Critically, it's not even fully clear whether or how GLP-1 molecules physically cross into the brain, meaning the mechanism may involve both direct brain action and gut-brain signaling. Khullar notes the gut-brain crosstalk — GLP-1 receptors in the pancreas, GI tract, and brain all play a role, and some addiction-relevant effects may come from signaling between the intestines and brain, not just the brain itself.

Manoush recalls the 1990s cultural shift when addiction began to be framed as genetic and neurobiological rather than a moral failing. She asks Khullar whether GLP-1s represent a new chapter in that evolution. He says yes — but stigma persists. Then he shares something deeply personal: he underwent the same fMRI protocol used with clinical trial participants, viewing photos of food and alcohol while his brain was scanned. The result was striking. His brain showed almost no activity in response to alcohol images; those with alcohol use disorder showed dramatically elevated responses in the same regions. That contrast — visceral, visual, and personal — drove home what years of medical training had only told him abstractly: much of addictive behavior is neurobiologically predetermined, happening before conscious decision-making even begins ^{[1] — Dhruv Khullar "Dhruv Khullar underwent the same MRI protocol as clinical trial participants, viewing images of food and alcohol while his brain was scanne…" 28:55 Play} .

Manoush asks about off-label GLP-1 use, and Khullar opens up the full breadth of emerging evidence. Beyond diabetes and obesity, studies are showing benefits for cardiovascular risk, stroke, fatty liver disease, chronic kidney disease, and even osteoarthritis ^{[1] — Dhruv Khullar "GLP-1 affects fatty liver, kidney disease: Studies show GLP-1 medications can slow or even reverse fatty liver disease and chronic kidney d…" 31:32 Play} . Some effects appear independent of weight loss entirely, pointing toward an anti-inflammatory mechanism. Khullar is careful to note he approached these claims with skepticism — and was surprised to find the evidence repeatedly holding up. He frames this as a genuinely novel drug class, not just another obesity pill, while warning that evidence is still catching up to real-world usage patterns.

When Manoush asks for the downsides, Khullar gives a thorough and balanced accounting. The adherence problem is fundamental — drugs only work if you take them, and more than half of patients stop within a year. Cost is a real barrier at up to $1,300 a month without insurance coverage. GI side effects may affect more people in the real world than clinical trials suggest. Muscle loss is clinically significant: rapid weight reduction strips away lean mass, increasing frailty risk, which is why Khullar recommends GLP-1 use be paired with high-protein diet and strength training ^{[1] — Dhruv Khullar "More than half of patients stop GLP-1 medications within a year, whether from side effects, cost, or access. The sticker price can hit $1,3…" 31:50 Play} . On long-term effects, he draws reassurance from the fact that exenatide, the first GLP-1 drug, launched around 2005–2006, giving the class a roughly 20-year track record — but acknowledges newer formulations may carry risks yet to surface.

Manoush raises two real-world encounters that made her uneasy. At an American Heart Association meeting, she heard researchers propose using GLP-1s preventively in kids in high-obesity communities — and worried this was reaching for a pharmaceutical quick fix before addressing root causes. At a separate conference of wealthy individuals, she saw GLP-1 use framed purely as optimization: not treating disease, but maximizing performance. Khullar validates both concerns. The evidence base for GLP-1s covers overweight adults and people with chronic conditions; preventive pediatric use and performance microdosing lack data entirely. More broadly, he worries that a sufficiently powerful drug becomes a political escape valve — reducing pressure to fix food systems, built environments, and social determinants of health. He's the first to want systemic change, he says, but also honest that decades of effort have yielded little progress, making the case for better access today.

Asked where GLP-1s are headed in the next year and beyond, Khullar paints an optimistic but measured picture of an expanding pipeline ^{[1] — Dhruv Khullar "Retatutride hits 3 receptors (vs. 1–2): A new Eli Lilly drug called retatutride hits three GLP-1-related receptors — compared to one or two…" 39:35 Play} . The current landscape is dominated by semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), but Eli Lilly's retatutride — a triple-receptor agonist targeting GLP-1, GIP, and glucagon — has already completed Phase 3 trials. Oral formulations are in development, removing the need for injection and likely improving adherence. The trajectory over 5–10 years is toward more options, better side-effect management, and reduced muscle loss — a far more personalized GLP-1 toolkit than exists today.

Manoush steps back to ask how GLP-1s fit within a larger arc of medical technology — alongside mRNA vaccines, CRISPR, and AI. Khullar sees AI as transformative for both drug development and clinical care, but raises a concern: as information multiplies and authority fragments, simply citing evidence is no longer enough to guide patients. He argues physicians must become storytellers — connecting data to real human lives, synthesizing complexity into narrative ^{[1] — Dhruv Khullar "As AI reshapes medicine, doctors can no longer simply state evidence and expect compliance. The information landscape is too fragmented and…" 43:00 Play} . He grounds this in his hospital experience: every social challenge — misinformation, homelessness, poverty — eventually presents in the ER. Doctors who can tell a compelling story will navigate that complexity; those who can't will be replaced by algorithms. He closes with a historical caution: approximately 90% of drugs reaching Phase 1 trials still fail, a reminder that even the most promising early data doesn't guarantee a therapy.

The conversation circles back to the TED Talk's philosophical core: Aristotle's virtue of moderation. Manoush asks whether GLP-1s remove human agency — handing responsibility for self-regulation to a molecule. Khullar reframes it: the modern world is architected for overconsumption, inundated with content, engineered food, and algorithmic stimulation ^{[1] — Dhruv Khullar "Aristotle never had a Dorito. He didn't have Krispy Kreme or McDonald's. He couldn't flip open TikTok and Instagram." 14:00 Play} . For many people, the problem isn't weak will — it's that the environment is stacked against moderation. GLP-1s aren't a bypass of agency; they restore the physiological conditions under which agency becomes possible. He illustrates this with a pre-GLP-1 patient memory: a taxi driver needing cardiac surgery but too obese to safely operate on. Everyone knew the 'lose weight and come back' instruction was effectively a death sentence. GLP-1s, Khullar reflects, might have given that man the bridge he needed. The key takeaway: for some, GLP-1s aren't a life sentence of pharmaceutical dependency — they're the catalyst for a reinvention.

Manoush wraps up by drawing out the episode's practical bottom line from Khullar: proceed cautiously, manage side effects proactively, and don't treat GLP-1s as a lifelong magic bullet. In her solo sign-off, she connects the episode to a broader theme — comparing GLP-1s to the unregulated peptide craze on social media and the geneticist Michael Snyder's advice to play the long game with health. The adage 'if it sounds too good to be true, it probably is' holds. She teases the next episode — artist Yiyun Kang using interactive AI art to make people feel the algorithms shaping their lives — and credits the full production team.

The episode ends with three sponsor reads: Toyota promotes its new all-electric vehicle family — including the bZ Woodland with dual motors and all-wheel drive — at toyota.com. Optum positions itself as simplifying healthcare through technology coordination, directing listeners to optum.com. Progressive Insurance closes with a repeat of its Name Your Price tool advertisement, directing listeners to progressive.com to find coverage that fits their budget.